Conchino Biologics Corporation announced the recent receipt of the Phase III clinical trial summary report for its development of the 13-price pneumococcal polyglucose-coupled vaccine (PCV13i). The vaccine uses innovative polyglycemic antigen and protein carrier co-binding technology to induce high levels of specific antibodies in infants and young children and generate immune memories. Phase III clinical trial results show that PCV13i has good safety and immunogenicity and has reached the default clinical endpoint. The Company will submit a production registration application to the National Drug Administration based on the results of the trial and will be subject to subsequent review and inspection procedures in order to place the product on the market. The Board urges shareholders and potential investors to exercise caution when trading shares. The announcement was issued by Chairman Xuefeng YU on January 30, 2024.

Conchino Biologics Corporation announced the recent receipt of the Phase III clinical trial summary report for its development of the 13-price pneumococcal polyglucose-coupled vaccine (PCV13i). The vaccine uses innovative polyglycemic antigen and protein carrier co-binding technology to induce high levels of specific antibodies in infants and young children and generate immune memories. Phase III clinical trial results show that PCV13i has good safety and immunogenicity and has reached the default clinical endpoint. The Company will submit a production registration application to the National Drug Administration based on the results of the trial and will be subject to subsequent review and inspection procedures in order to place the product on the market. The Board urges shareholders and potential investors to exercise caution when trading shares. The announcement was issued by Chairman Xuefeng YU on January 30, 2024.